Laura Hamill
CIK 1751804 · EVP, Worldwide Commercial Ops · last filed 2026-08-07
Laura Hamill is an EVP, Worldwide Commercial Ops who has filed 28 SEC Form 4 insider transactions across 8 companies since 2018. The most recent filing, for JAZZ, was dated Aug 7, 2026. Current disclosed insider exposure totals $3.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.50M
8
28
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 8,538 | $256.56 | $2.19M | $0 | 3 | 2026-08-07 |
| FATE | Director | — | $2.80 | — | $0 | 1 | 2026-06-15 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 30,905 | $8.61 | $266.1K | $0 | 6 | 2025-07-02 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | Director | — | $2.16 | — | $0 | 4 | 2023-08-31 |
| SCLXW | Director | — | $0.21 | — | $0 | 1 | 2023-01-17 |
| ANAB | Director | — | $56.61 | — | $0 | 5 | 2023-01-10 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | $0 | 3 | 2021-11-22 |
| GILD | EVP, Worldwide Commercial Ops | 9,840 | $133.21 | $1.31M | $0 | 3 | 2019-05-10 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-07 | JAZZ | Grant (A) | +1,605 | $0 | EDGAR |
| 2026-06-15 | FATE | Grant (A) | — | $0 | EDGAR |
| 2025-09-19 | — | Mixed | −30,905 | -$50.1K | |
| 2025-08-11 | JAZZ | Mixed | +1,702 | -$200.8K | EDGAR |
| 2025-08-08 | JAZZ | Notice (144) | −3,731 | -$417.9K | EDGAR |
| 2025-07-02 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +25,080 | $0 | EDGAR |
| 2024-08-06 | JAZZ | Grant (A) | +3,731 | $0 | EDGAR |
| 2024-06-13 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +3,495 | $0 | EDGAR |
| 2023-08-31 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-06-09 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +2,330 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.